So far this year, Pfizer shares have fallen about 12.3%.
Carlos Osorio/POOL/AFP via Getty Images
Pfizer
and
BioNTech SE
announced Friday an FDA fast track designation for a single-dose Covid and flu vaccine candidate.
The companies earlier began a Phase 1 trial to determine the safety of the candidate in healthy adults.
The candidate provides protection against the BA.4/BA.5 Omicron sublineages and four different influenza strains — as recommended for use in the northern hemisphere by the World Health Organization.
The announcement comes after the FDA Thursday authorized the updated bivalent
Pfizer
and Moderna Covid-19 vaccines for children as young as six months. This age revision lowers
Pfizer
‘s previous authorization for children over four and Moderna’s of six years old and up.
Pfizer stock (ticker: PFE) stayed flat in premarket trading Friday, while
BioNTech
(BNTX) dipped 0.3%. So far this year, Pfizer shares have fallen 12.3%, and BioNTech shares have fallen 33.4%, as of Thursday’s close.
Write to Emily Dattilo at emily.dattilo@dowjones.com
Credit: marketwatch.com